Pelosi’s radical plan leaves lung cancer patients behind
By Tom Wilbur | October 23, 2019
Lung cancer is the second most common form of cancer in men and women and the leading cause of cancer-related deaths in the United States. In 2019 alone, there will be an estimated 228,000 new...
Read More
Pelosi’s radical plan would leave Alzheimer’s patients behind
By Tom Wilbur | October 16, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...
Read More
Event tomorrow: Maintaining America’s leadership in access and innovation
By Andrew Powaleny | October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high...
Read More
What They Are Saying: Broad Opposition to Pelosi’s Radical Drug Pricing Plan
By Tom Wilbur | October 10, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan that would be the wrong approach for patients, the U.S. health care system, economy, and American innovation. An...
Read More
By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk
By Tom Wilbur | September 26, 2019
We already know that the radical drug pricing plan unveiled last week by House Speaker Nancy Pelosi is the wrong approach for patients, the U.S. health care system, and American innovation. But...
Read More
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
By Guest Contributor | September 4, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New Report: Advanced manufacturing powering innovative biopharmaceuticals
By Tim McClung | May 10, 2019
The science-based advanced manufacturing infrastructure of the biopharmaceutical industry is critical to fueling the innovation necessary to bring new treatments and cures to patients. With a...
Read More
Clinical trials impact state economies
By John Corea | May 3, 2019
A new report from TEConomy Partners, supported by PhRMA, provides estimates of industry-sponsored clinical trial activity in each of the 50 states, including the number of trials active, the...
Read More
Biopharmaceutical venture capital is spurring innovation and economic growth
By Tim McClung | February 11, 2019
The biopharmaceutical ecosystem has helped make the U.S. the global leader in biomedical innovation today. An important part of this ecosystem is the thousands of small startup biopharmaceutical...
Read More
In survey, PhRMA member companies highlight impact of IPI on R&D
By Katie Verb | February 5, 2019
One of the biggest myths regarding the administration’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D)....
Read More
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
